. Author manuscript; available in PMC: 2014 Feb 26.

Published in final edited form as: Sci Transl Med. 2013 Jul 31;5(196):196ra99. doi: 10.1126/scitranslmed.3005747

Table 2. Clinical information and mutational status in six patients with available paired tumor biopsies before and after therapy with BYL719.

Best tumor response was defined as maximum tumor volume change compared to pretreatment control and was determined per RECIST criteria. Pre, biopsy before the first dose of BYL719; post, biopsy collected at day 56 of treatment. pS6 was measured by H-score.

Patient no.	Tumor subtype	Age	No. of previous therapies	BYL719 dose (mg)	PIK3CA-mut	pS6 pre	pS6 post	Best response	Lesion biopsied
1	ER⁺/PR⁺/HER2⁺	42	1	180	H1047R	300	285	−1.50%	Breast
2	ER⁺/PR⁺/HER2⁺	49	2	400	H1047R	285	225	−8.40%	Liver
3	ER⁺/PR⁺/HER2⁻	55	6	450	H1047R	150	230	+7.89%	Liver
4	ER⁺/PR⁺/HER2⁻	53	2	400	G1049Ar	145	70	−34.80%	Breast
5	ER⁺/PR⁺/HER2⁺	51	3	400	H1047R	300	75	−26.30%	Breast
6	ER⁺/PR⁻/HER2⁻	48	1	400	H1047R	285	140	−24.90%	Breast